Downregulation and hypermethylation of TET2 were further linked to worse CRC prognosis, while high TET2 expression enriched immune-regulatory pathways (Th1/Th2/Th17 differentiation, antigen presentation, NF-κB signaling) [23]. This evidence concerns the gene TET2 and colorectal carcinoma.